Welcome to our dedicated page for Meiragtx Holdings Plc SEC filings (Ticker: MGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MeiraGTx Holdings plc (Nasdaq: MGTX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage genetic medicines company with programs in ophthalmology, Parkinson’s disease and radiation-induced xerostomia, MeiraGTx uses SEC reports to communicate material events, financial results and key collaboration agreements to investors.
Among the filings available are current reports on Form 8-K, which MeiraGTx has used to announce quarterly financial and operational results, strategic collaborations and regulatory milestones. For example, the company has filed 8-Ks describing its strategic collaboration and license agreement with Eli Lilly and Company in ophthalmology, its broad collaboration with Hologen Limited to form Hologen Neuro AI Ltd, and the receipt of foreign direct investment clearances related to that collaboration. Other 8-Ks reference the release of financial results for specific quarters.
In addition to current reports, investors can use this page to locate MeiraGTx’s periodic filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, when available. These documents typically contain detailed discussions of the company’s clinical pipeline, including programs like AAV-AIPL1, AAV2-hAQP1 and AAV-GAD, as well as risk factors, management’s discussion and analysis, and information on its manufacturing infrastructure and collaborations.
Stock Titan enhances access to these filings by providing real-time updates from the SEC’s EDGAR system and AI-powered summaries that explain the key points in plain language. Users can quickly see which filings relate to clinical data, regulatory designations, strategic partnerships or financing. The filings page also surfaces information on items such as material definitive agreements, like the collaboration and license agreement with Eli Lilly, and other disclosures that may affect MeiraGTx’s development plans and capital position.
For those tracking MeiraGTx’s progress in genetic medicine, this page offers a structured view of how the company reports its activities to regulators and the market, from clinical and regulatory milestones to manufacturing and partnership developments.
MeiraGTx (MGTX) announced a strategic collaboration and license with Eli Lilly focused on ophthalmology genetic medicines. MeiraGTx will receive an upfront payment of $75 million and is eligible for up to over $400 million in total milestone payments, including up to $135 million tied to development and regulatory milestones. Lilly receives exclusive, worldwide rights to develop and commercialize the AAV-AIPL1 program for LCA4 and two additional preclinical retinal candidates.
Lilly also receives exclusive licenses to proprietary intravitreal capsids and pan‑retinal/rod‑specific promoters for up to five ophthalmology targets each, plus a right of first designation on certain target-specific transactions and a right of first negotiation for MeiraGTx’s riboswitch technology in ophthalmological gene editing. Lilly will fund research, development and commercialization, and MeiraGTx Ocular will receive tiered royalties. The agreement includes standard IP ownership provisions and is terminable for uncured material breach; Lilly may also terminate in whole, by product, or by country with notice.
MeiraGTx Holdings plc (MGTX) reported an insider transaction: CFO & COO Richard Giroux sold 24,000 ordinary shares on Oct 21, 2025 at a $8.87 weighted average pursuant to a Rule 10b5-1 trading plan adopted Aug 29, 2024.
Sale prices ranged from $8.65 to $9.06. After the transaction, he beneficially owns 829,494 shares directly, plus 5,152 indirectly via spouse and 85,000 indirectly via Aigle Healthcare Partners III LLC.
Insider sale by a senior officer: Alexandria Forbes, listed as President & CEO and a director, reported a sale of 47,500 ordinary shares of MeiraGTx Holdings plc (MGTX) on
The filing shows a weighted average sales price of
MeiraGTx Holdings (MGTX) filed a Form 144 notice for the proposed sale of 47,500 ordinary shares under Rule 144. The filing lists an aggregate market value of $398,525 and an approximate sale date of 10/07/2025. The broker named is Merrill Lynch, 200 Park Avenue, New York, NY 10166, and the shares are listed on NASDAQ.
The securities to be sold were acquired on 06/07/2018 via an incentive compensation stock grant from the issuer, with 47,500 shares acquired on that date. As context, the filing states 80,447,477 shares were outstanding.
MeiraGTx reported continued operating losses as it advances its gene-therapy pipeline and manufacturing business. For the six months ended June 30, 2025 the company recorded a $78.8 million net loss and used $80.8 million of cash from operations. Cash, cash equivalents and restricted cash totaled $34.4 million at June 30, 2025 and the balance sheet showed a $780.8 million accumulated deficit, leaving shareholders' equity at $3.0 million.
Strategically, MeiraGTx signed a March 9, 2025 collaboration with Hologen that contemplates a $200 million upfront payment and up to $230 million of additional funding; Hologen made a $6.0 million payment in June 2025 and an additional $17.0 million payment in the third quarter of 2025, and the parties expect the transaction to close in the third calendar quarter of 2025, subject to customary conditions. The company also retains a supply agreement and contingent payments tied to the prior asset sale to Johnson & Johnson (an initial $65.0 million upfront in 2023 and $60.0 million in milestones received in 2024, with up to $350.0 million of contingent consideration remaining). Management states available cash, receivables, the $17.0 million deposit received and anticipated remaining collaboration proceeds are expected to be sufficient to fund operations for at least the next twelve months.
MeiraGTx Holdings plc furnished an 8-K after releasing its financial results for the quarter ended June 30, 2025. The company reported these quarterly results in a press release dated August 14, 2025, which is attached as Exhibit 99.1 and incorporated by reference. The press release and related materials are designated as furnished rather than filed, meaning they are not subject to certain Exchange Act liability provisions unless specifically incorporated into other filings.
MeiraGTx Holdings plc (MGTX) – Form 4 insider transaction
President & CEO Alexandria Forbes reported the sale of 47,500 ordinary shares of MGTX on 8 July 2025. The shares were disposed of at a weighted-average price of $7.97 per share (individual trade prices ranged from $7.73 to $8.15). The transaction was executed under a Rule 10b5-1 trading plan adopted 21 Aug 2024, indicating it was pre-scheduled and not the result of ad-hoc decision-making.
Following the sale, Forbes’ direct beneficial ownership stands at 1,361,483 ordinary shares. No derivative securities were involved in this filing, and no additional transactions were reported.
The gross proceeds of the reported sale, based on the disclosed weighted-average price, total roughly $379 thousand. Forbes continues to serve as both Director and President & CEO of MeiraGTx.
Form 144 filing overview for MeiraGTx Holdings plc (MGTX)
The notice discloses a proposed sale of 47,500 ordinary shares through Merrill Lynch, 200 Park Avenue, New York, NY 10166. The transaction is scheduled for approximately 08 July 2025 on the NASDAQ exchange.
- Aggregate market value: $378,575
- Total shares outstanding: 80,365,359
- Percentage of float affected: ≈0.06%
The shares were originally acquired via incentive compensation stock grants on 02 March 2018 (35,625 shares) and 07 June 2018 (11,875 shares). The filer reports no other share sales within the past three months.
Because the sale represents a small fraction of outstanding stock and stems from equity compensation, the filing is generally considered routine. Investors often monitor Form 144s to gauge insider sentiment; however, the scale here is unlikely to materially impact market dynamics.
SEC Form 4 for MeiraGTx Holdings plc (MGTX) discloses that Richard Giroux, the company’s Chief Financial & Operating Officer, gifted 5,000 ordinary shares on 06/30/2025 (transaction code G, price $0). After this transaction, Giroux still owns 877,494 shares directly and 90,152 shares indirectly (5,152 via spouse; 85,000 via Aigle Healthcare Partners III LLC). No derivative positions were added or reduced, and the filing was signed on 07/02/2025. The Rule 10b5-1 checkbox is not marked, indicating the gift was not executed under a preset trading plan. The transaction reduces Giroux’s direct stake by approximately 0.6%, leaving his overall ownership essentially unchanged. There is no indication of operational or financial impact on MeiraGTx arising from this personal transfer.
MeiraGTx (NASDAQ:MGTX) filed an 8-K Regulation FD disclosure announcing it has obtained all required UK foreign-direct-investment clearances for its previously announced transactions with Hologen Ltd., signed March 9 2025.
The clearance removes the final regulatory hurdle, allowing the deal—which management expects to close in July 2025—to proceed to funding and execution.